The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group

Leukemia Research
Anna DmoszynskaJanusz Kloczko

Abstract

Multiple myeloma (MM) remains an incurable disease, but response rates to new drugs are promising, offering the majority of patients a significant prolongation of overall survival. The objective of this study was to evaluate time to progression (TTP), event-free survival (EFS), and overall survival (OS) in MM patients treated with a combination of cyclophosphamide (CY), thalidomide (THAL) and dexamethasone (DEX). This study included 132 untreated and relapsing/resistant patients treated with the low-thalidomide dose CTD regimen. The patients received CY 500 mg/m(2)i.v. or 625 mg/m(2) orally at day 1, THAL 100mg/day á la longue and DEX 20mg/day at days 1-4 and 8-11, every 28 days. Patients received 6-9 cycles; ORR by 3 months was 59.1%, by 6 months 65.6% and by 9 months 75.6%. In patients responding to CTD therapy (CR, nCR, PR), the probability of survival for 20 months was 89.3%. The outpatient low-thalidomide dose CTD regimen is well tolerated and produces a significant response rate both in untreated and relapsing/resistant MM patients.

References

Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Aug 20, 2002·Blood·Xavier LeleuIbrahim Yakoub-Agha
Jun 5, 2003·British Journal of Haematology·Athanasios AnagnostopoulosRaymond Alexanian
Mar 16, 2004·Seminars in Hematology·Raymond AlexanianKim Rankin
Mar 30, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Meletios A DimopoulosAthanasios Anagnostopoulos
Aug 7, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Antonio PalumboMario Boccadoro

❮ Previous
Next ❯

Citations

Aug 27, 2011·Thrombosis Research·Lukasz BolkunJanusz Kloczko
Dec 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Norbert GrzaskoMarek Hus
Jul 17, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dan WangQiang Zhang
Mar 14, 2012·Bone Marrow Transplantation·B WirkJ S Moreb

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
Y YangZ-T Zhou
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Murali ChintagumpalaStacey L Berg
© 2021 Meta ULC. All rights reserved